Table I.

Characteristics of patients who received leflunomide for treatment of vasculitis (n=93).

Characteristics	Values
Demographic features
Age at diagnosis, 4 mean ± SD [range], years	48 ± 19.3 [4–80]
Number of females	66 (71%)
Race
Caucasian	73 (79%)
Asian	6 (7%)
Black or African American	4 (4%)
Vasculitis diagnosis
Granulomatosis with polyangiitis	45 (48%)
ANCA-positive	31 (33%)
Microscopic polyangiitis	8 (9%)
ANCA-positive	8 (9%)
Eosinophilic granulomatosis with polyangiitis	12 (13%)
Takayasu’s arteritis	9 (10%)
Giant cell arteritis	14 (15%)
Polyarteritis nodosa	5 (5%)
Previous treatments
Glucocorticoids	87 (94%)
Oral or intravenous cyclophosphamide	65 (70%)
Methotrexate	64 (69%)
Azathioprine	51 (55%)
Rituximab	15 (16%)
Mycophenolate mofetil	12 (13%)
Infliximab	6 (7%)
Others*	21 (23%)

Data are n (%) of patients, unless otherwise indicated.

^*n=4: hydroxychloroquine; n=4: intravenous immunoglobulin; n=3: plasma exchange; n=3: etanercept; n=2: tocilizumab; n=3: sulfasalazine; n=1: cyclosporine; and n=1: eculizumab (in a paediatric patient with severe refractory GPA).